Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index; 27 of the 41 sources its claims cite were checked for support.
Abstract
BACKGROUND: Familial chylomicronemia syndrome is a genetic disorder associated with severe hypertriglyceridemia and severe acute pancreatitis. Olezarsen reduces the plasma triglyceride level by reducing hepatic synthesis of apolipoprotein C-III. METHODS: In a phase 3, double-blind, placebo-controlled trial, we randomly assigned patients with genetically identified familial chylomicronemia syndrome to receive olezarsen at a dose of 80 mg or 50 mg or placebo subcutaneously every 4 weeks for 49 weeks. There were two primary end points: the difference between the 80-mg olezarsen group and the placebo group in the percent change in the fasting triglyceride level from baseline to 6 months, and (to be assessed if the first was significant) the difference between the 50-mg olezarsen group and the placebo group. Secondary end points included the mean percent change from baseline in the apolipoprotein C-III level and an independently adjudicated episode of acute pancreatitis. RESULTS: A total of 66 patients underwent randomization; 22 were assigned to the 80-mg olezarsen group, 21 to the 50-mg olezarsen group, and 23 to the placebo group. At baseline, the mean (±SD) triglyceride level among the patients was 2630±1315 mg per deciliter, and 71% had a history of acute pancreatitis within the previous 10 years. Triglyceride levels at 6 months were significantly reduced with the 80-mg dose of olezarsen as compared with placebo (-43.5 percentage points; 95% confidence interval [CI], -69.1 to -17.9; P<0.001) but not with the 50-mg dose (-22.4 percentage points; 95% CI, -47.2 to 2.5; P = 0.08). The difference in the mean percent change in the apolipoprotein C-III level from baseline to 6 months in the 80-mg group as compared with the placebo group was -73.7 percentage points (95% CI, -94.6 to -52.8) and between the 50-mg group as compared with the placebo group was -65.5 percentage points (95% CI, -82.6 to -48.3). By 53 weeks, 11 episodes of acute pancreatitis had occurred in the placebo group, and 1 episode had occurred in each olezarsen group (rate ratio [pooled olezarsen groups vs. placebo], 0.12; 95% CI, 0.02 to 0.66). Adverse events of moderate severity that were considered by a trial investigator at the site to be related to the trial drug or placebo occurred in 4 patients in the 80-mg olezarsen group. CONCLUSIONS: In patients with familial chylomicronemia syndrome, olezarsen may represent a new therapy to reduce plasma triglyceride levels. (Funded by Ionis Pharmaceuticals; Balance ClinicalTrials.gov number, NCT04568434.).
Overview
CoChat Summary
TL;DR
In a phase 3 trial of patients with genetically identified familial chylomicronemia syndrome, olezarsen 80 mg every 4 weeks significantly reduced fasting triglycerides at 6 months versus placebo, while the 50-mg dose did not. Olezarsen also reduced apolipoprotein C-III and was associated with fewer adjudicated acute pancreatitis episodes over 53 weeks.
Key findings
- The 80-mg olezarsen group had a least-squares mean reduction in fasting triglycerides from baseline to 6 months of −43.5 percentage points versus placebo (95% CI, −69.1 to −17.9; P<0.001); the 50-mg dose did not meet significance (−22.4 percentage points; 95% CI, −47.2 to 2.5; P=0.08).
- Apolipoprotein C-III reductions from baseline to 6 months were −73.7 percentage points for 80 mg vs placebo (95% CI, −94.6 to −52.8) and −65.5 percentage points for 50 mg vs placebo (95% CI, −82.6 to −48.3).
- By 53 weeks, adjudicated acute pancreatitis occurred in 11 episodes in the placebo group and 1 episode in each olezarsen group (rate ratio for pooled olezarsen vs placebo, 0.12; 95% CI, 0.02 to 0.66).
- Adverse events of moderate severity considered related to trial drug or placebo occurred in 4 patients (18%) in the 80-mg olezarsen group.
Methods
- Phase 3, double-blind, placebo-controlled trial conducted from November 2020 through October 2023 at 29 centers in 11 countries; 66 patients with genetically identified familial chylomicronemia syndrome were randomized to olezarsen 80 mg (n=22), olezarsen 50 mg (n=21), or placebo (n=23) subcutaneously every 4 weeks for 49 weeks.
- Patients had fasting triglycerides ≥880 mg/dL and biallelic loss-of-function variants in LPL or related genes; baseline mean triglyceride level was 2630±1315 mg/dL, and 71% had a history of acute pancreatitis within the previous 10 years.
- Primary endpoints were hierarchical: difference between 80 mg and placebo in percent change in fasting triglycerides from baseline to 6 months, then the same for 50 mg vs placebo; secondary endpoints included apolipoprotein C-III change and independently adjudicated acute pancreatitis.
Limitations
- The paper states the trial cohort was small and there was uncertainty about adherence to dietary restrictions, which could have affected triglyceride lowering and acute pancreatitis incidence.
- The paper states the trial included mostly White patients, partly owing to genetic founder effects in European populations, and that larger, more diverse trials are needed.
- The paper notes that because the second primary endpoint was not significant, secondary endpoint results cannot be interpreted as definitive hypothesis tests and their confidence intervals were not adjusted for multiplicity; it also states postprandial fluctuations were not measured.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
15 Valid · 3 Not valid · 7 Not checked · 64 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Olezarsen is an investigational GalNAc 3 -conjugated antisense oligonucleotide that reduces apolipoprotein C-III production by binding to APOC3 mRNA and inducing its degradation through ribonuclease H1-mediated cleavage of the sense strand. 26,28,29”
What the sources say
- Not checked — no full text of the sourcecites [26] 26. Crooke ST, Witztum JL, Bennett CF, Baker BF. RNA-targeted therapeutics. Cell Metab 2018; 27: 714-39. source
- Partly supportedcites [28] matched to “N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels” (2019) sourceExperimental — accuracy not yet measured
The Introduction describes AKCEA-APOCIII-LRx as a GalNAc3-modified antisense oligonucleotide targeting hepatic APOC3 mRNA, and the Discussion reports reduced plasma apoC-III. Our copy does not identify it by the name olezarsen or describe ribonuclease H1-mediated cleavage of the sense strand; those details are not supported by this source. (LLM, conf=0.86)
- Partly supportedcites [29] 29. Tardif JC, Karwatowska-Prokopczuk E, Amour ES, et al. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur Heart J 2022; 43: 1401-12. 30. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17: 405-24. sourceExperimental — accuracy not yet measured
The Introduction (p. 4) identifies olezarsen as a GalNAc-conjugated antisense oligonucleotide targeted to hepatic APOC3 mRNA to inhibit apoC-III production. Our copy does not specify that its conjugate is GalNAc3 or describe mRNA degradation through ribonuclease H1-mediated cleavage of the sense strand. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The condition is caused by biallelic loss-of-function variants in LPL (encoding lipoprotein lipase) or in related genes needed for LPL activity. 10-12”
What the sources say
- Supportedcites [10] 10. patients with familial chylomicronemia syndrome using FCS score-based data mining methods. J Clin Med 2022; 11: 4311. 10. Moulin P, Dufour R, Averna M, et al. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): expert panel recommendations and proposal of an 'FCS score.' Atherosclerosis 2018; 275: 265-72. source
The Introduction (p. 2) identifies homozygous or compound-heterozygous loss-of-function mutations in LPL and genes involved in LPL function as causes of FCS. Disease classification (p. 3) also lists homozygous loss-of-function mutations in related genes and compound-heterozygous mutations. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [11] matched to “Genetic testing in dyslipidemia: A scientific statement from the National Lipid Association” (2020) source
- Supportedcites [12] 12. Stroes E, Moulin P, Parhofer KG, Rebours V, Löhr JM, Averna M. Diagnostic algorithm for familial chylomicronemia syndrome. Atheroscler Suppl 2017; 23: 1-7. source
Section 1.1 describes FCS as an autosomal recessive monogenic disease caused by mutations in genes encoding key molecules of the lipolytic cascade. Sections 1.2 and 3 identify LPL and four genes needed for its activity as causes when mutated and dysfunctional. The paper does not use the exact phrase “biallelic loss-of-function,” but its description supports that paraphrase. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Loss of LPL activity results in a reduced ability to hydrolyze triglycerides in triglyceride-rich lipoproteins, such as intestinally derived chylomicrons and hepatically derived very-low-density lipoproteins, leading to their accumulation in plasma and subsequent severe hypertriglyceridemia. 10-12”
What the sources say
- Partly supportedcites [10] 10. patients with familial chylomicronemia syndrome using FCS score-based data mining methods. J Clin Med 2022; 11: 4311. 10. Moulin P, Dufour R, Averna M, et al. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): expert panel recommendations and proposal of an 'FCS score.' Atherosclerosis 2018; 275: 265-72. sourceExperimental — accuracy not yet measured
The Introduction (p. 2) says LPL hydrolyses triglycerides and that loss of LPL function impairs clearance of intestinally derived chylomicrons. Disease classification (p. 3) links LPL deficiency in FCS with severe, persistent hypertriglyceridemia. Our copy does not establish the citing sentence’s additional point about hepatically derived VLDL accumulating through this mechanism. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [11] matched to “Genetic testing in dyslipidemia: A scientific statement from the National Lipid Association” (2020) source
- Supportedcites [12] 12. Stroes E, Moulin P, Parhofer KG, Rebours V, Löhr JM, Averna M. Diagnostic algorithm for familial chylomicronemia syndrome. Atheroscler Suppl 2017; 23: 1-7. source
Section 1.2 states that LPL hydrolyzes triglycerides in chylomicrons and VLDL. Section 3 links impaired lipolysis of triglyceride-rich lipoproteins to chylomicronemia, and Section 2 reports severe hypertriglyceridemia in patients with LPL deficiency. Together, these passages support the attributed causal chain. (LLM, conf=0.91)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“and these agents have not been effective in lowering triglyceride levels in patients with familial chylomicronemia syndrome. 21,34”
What the sources say
- Not checked — no full text of the sourcecites [21] 21. Hegele RA. Apolipoprotein C-III inhibition to lower triglycerides: one ring to rule them all? Eur Heart J 2022; 43: 1413-5. source
- Could not verifycites [34] 34. Borén J, Packard CJ, Taskinen MR. The roles of ApoC-III on the metabolism of triglyceride-rich lipoproteins in humans. Front Endocrinol (Lausanne) 2020; 11: 474. sourceExperimental — accuracy not yet measured
The Pharmacological Interventions section says fibrates have variable effects on APOC3 expression and omega-3 fatty acids moderately reduce apoC-III levels. It reports triglyceride lowering in familial chylomicronemia syndrome with volanesorsen, but does not address whether fibrates or omega-3 fatty acids fail to lower triglycerides in those patients (searched for familial chylomicronemia and conventional treatments). (LLM, conf=0.74)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Olezarsen reduces the plasma triglyceride level by reducing hepatic synthesis of apolipoprotein C-III.”
What the sources say
- Not checked — no full text of the sourcecites [26] 26. Crooke ST, Witztum JL, Bennett CF, Baker BF. RNA-targeted therapeutics. Cell Metab 2018; 27: 714-39. source
- Supportedcites [28] matched to “N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels” (2019) source
The Discussion reports that AKCEA-APOCIII-LRx targets APOC3 mRNA and significantly lowers plasma apoC-III and triglycerides in subjects with hypertriglyceridaemia. The paper describes the drug as hepatocyte-targeted and as inhibiting apoC-III protein synthesis. It uses the developmental name AKCEA-APOCIII-LRx rather than olezarsen. (LLM, conf=0.87)
- Supportedcites [29] 29. Tardif JC, Karwatowska-Prokopczuk E, Amour ES, et al. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur Heart J 2022; 43: 1401-12. 30. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17: 405-24. source
The Introduction (p. 4) states that olezarsen targets hepatic APOC3 mRNA to inhibit apoC-III protein production. The Methods and results (p. 2) report significant reductions in fasting triglyceride levels with olezarsen compared with placebo. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
36 more claims · 4 with their cited sources checked
Create a free account to see all 89 claims and every source verdict.
- Probably not a substantial claim. 26
- It may state two separate claims as one. 33
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“LDL Cholesterol(LDL-C) increased significantly in the olezarsen group at 6 months (MD = 52.75%;95% CI: 42.17, 63.33; P=.00001;I 2 = 31%)”
From Efficacy of Olezarsen in Severe Hypertriglyceridemia and Acute Pancreatitis Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (2026) · cites this paper as [8]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“and at 12 months (MD = -22.90%;95% CI: -26.47, -19.32;P=.0001;I 2 = 0%)”
From Efficacy of Olezarsen in Severe Hypertriglyceridemia and Acute Pancreatitis Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (2026) · cites this paper as [8]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Sensitivity analyses excluding patients with familial chylomicronemia syndrome demonstrated that statistically significant reductions in the mean percentage change from baseline in TG and apolipoprotein C-III levels persisted, although substantial heterogeneity remained”
From Efficacy of Olezarsen in Severe Hypertriglyceridemia and Acute Pancreatitis Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (2026) · cites this paper as [8]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Subgroup analyses evaluating dose-dependent effects showed significant reductions in TG levels at both the 50-mg dose (MD = -50.81;95% CI: -63.28, -38.34;P = .0001;I² = 64%)”
From Efficacy of Olezarsen in Severe Hypertriglyceridemia and Acute Pancreatitis Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (2026) · cites this paper as [8]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Sensitivity analyses excluding patients with familial chylomicronemia syndrome demonstrated that statistically significant reductions in the mean percentage change from baseline in TG and apolipoprotein C-III levels persisted, although substantial heterogeneity remained”
From Efficacy of Olezarsen in Severe Hypertriglyceridemia and Acute Pancreatitis Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (2026) · cites this paper as [8]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured
31 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2015.30 · Cited by 32,594
Banks, P. A., Bollen, T. L., Dervenis, C., Gooszen, H. G., Johnson, C. D., Sarr, M. G., Tsiotos, G. G., & Vege, S. S. (2013) · Gut · doi:10.1136/gutjnl-2012-302779 · Cited by 7,187
Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
The TG and HDL Working Group of the Exome Sequencing Project, N. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1307095 · Cited by 1,071
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308027 · Cited by 919
Crooke, S. T., Witztum, J. L., Bennett, C. F., & Baker, B. F. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.004 · Cited by 841
Self-citationPollin, T. I., Damcott, C. M., Shen, H., Ott, S. H., Shelton, J., Horenstein, R. B., Post, W., McLenithan, J. C., Bielak, L. F., Peyser, P. A., et al. (2008) · Science · doi:10.1126/science.1161524 · Cited by 688
Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
Witztum, J. L., Gaudet, D., Freedman, S. D., Alexander, V. J., Digenio, A., Williams, K. R., Yang, Q., Hughes, S. G., Geary, R. S., Arca, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1715944 · Cited by 669
Self-citationHegele, R. A., Ginsberg, H. N., Chapman, M. J., Nordestgaard, B. G., Kuivenhoven, J. A., Averna, M., Borén, J., Bruckert, E., Catapano, A. L., Descamps, O. S., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70191-8 · Cited by 635
Self-citationAntisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
Gaudet, D., Alexander, V. J., Baker, B. F., Brisson, D., Tremblay, K., Singleton, W., Geary, R. S., Hughes, S. G., Viney, N. J., Graham, M. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1400283 · Cited by 528
Self-citationTargeting APOC3 in the familial chylomicronemia syndrome
Gaudet, D., Brisson, D., Tremblay, K., Alexander, V. J., Singleton, W., Hughes, S. G., Geary, R. S., Baker, B. F., Graham, M. J., Crooke, R. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400284 · Cited by 491
Self-citation
Research works printed but not linked: 1
- 11. United States adults. Am J Cardiol 2011; 107: 891-7.
Cited by
Items 101–200 of 267
Advancing Gene Therapy for Pancreatitis: From Genetic Insights to Clinical Translation
Zheng, Y.-Z., Wang, Y., Qi, H.-M., Gao, J., Li, Z., Liao, Z., & Zou, W. (2026) · Research · doi:10.34133/research.1154 · Cited by 5
“%) levels during a 6-month observation period, with fewer AP events than placebo by 53 weeks [ 74 ].”
Loomba, R. S., de‐Madaria, E., Afghani, E., Singh, V. K., & Leeper, N. J. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70623 · Cited by 5
New and Emerging Therapeutic Targets for ApoB-Containing Particles Lowering
Gaudet, D., Larouche, M., Raal, F. J., & Catapano, A. L. (2026) · Circulation Research · doi:10.1161/circresaha.126.327270 · Cited by 5
Olezarsen and Plozasiran in Dyslipidemia Management: A Narrative Review of Clinical Trials
Olatunji, G. D., Ogieuhi, I. J., Kokori, E., Ajekiigbe, V. O., Ajimotokan, O. I., Odukudu, G.-D. O., Owolabi, S., Anyacho, S., Nwakama, C., Babalola, A. E., et al. (2024) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-024-00677-7 · Cited by 4
Pan, Z., Zaman, M. A., Kalsoom, S., & Zhang, Y. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2423724 · Cited by 4
“● GalNAc-conjugated ASO therapies hold significant promise for developing effective liver-targeted treatments in the future. been shown to reduce triglycerides by 43.5% in patients with familial chylomicronemia syndrome ( n = 66, p < 0.001), but not the 50 mg monthly group (−22.4%, p = 0.08) [30].”
InfluentialKølle, I. S., Hesthaven, A. S., Davidsen, L., et al. (2025) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2025.2485135 · Cited by 4
“Lipid-lowering therapies have been shown to reduce the risk of RAP in patients with severe hypertriglyceridemia [28,29].”
Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk
Watts, G. F., Hegele, R. A., & Leeper, N. J. (2025) · New England Journal of Medicine · doi:10.1056/nejmc2412616 · Cited by 5
Self-citationPancreatitis Secondary to Dyslipidemia: An Understudied Condition
Jacobs, T. H., Wayne, C. D., Sajankila, N., & Narayanan, S. (2024) · Lipidology · doi:10.3390/lipidology1020009 · Cited by 3
“It has been shown in a recent trial that in patients with FCS, Olezarsen may represent a new therapy to reduce plasma TG levels by reducing the hepatic synthesis of APOC3 [115].”
Diagnosis, Evaluation, and Management of Severe Hypertriglyceridemia
Krishnamurthy, A., Homan, E. A., & Kim, S. M. (2025) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-025-00758-9 · Cited by 5
“Of note, there was a small increase in LDL-C in the olezarsen arm and the clinical significance of which is unclear [57].”
Serag, I., Alkhawaldeh, I. M., Shati, A. A., Alqahtani, Y. A., Alattar, A., Khader Alkhamaiseh, S. A., & Moawad, M. H. E. D. (2026) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-025-04406-2 · Cited by 3
“Olezarsen has also been shown to significantly lower triglyceride levels in adult patients diagnosed with familial chylomicronemia syndrome, a rare genetic disorder characterized by severe hypertriglyceridemia (Stroes et al. 2024).”
Nelson, J. R. (2025) · Cardiology Plus · doi:10.1097/cp9.0000000000000130 · Cited by 3
Joubert, S., Ninan, J., Rosario, N., Davis, S. R., Wollen, J. T., & Wang, E. M. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00774-5 · Cited by 4
Ballantyne, C. M., Baass, A. W., Rosenson, R. S., Hegele, R. A., Nicholls, S. J., Vasas, S., Clifton, P. M., Lucas, K. J., Páll, D., Zhou, R., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101523 · Cited by 3
Self-citationGinsberg, H. N., & Bornfeldt, K. (2026) · Circulation Research · doi:10.1161/circresaha.125.327267 · Cited by 4
Self-citationRNA-based therapies targeting APOC3 lower triglyceride levels in patients with hypertriglyceridaemia
Huynh, K. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01034-w · Cited by 3
Reducing the Risk of Pancreatitis by Inhibiting APOC3
Stitziel, N. O. (2025) · New England Journal of Medicine · doi:10.1056/nejme2411605 · Cited by 5
Guo, J. (2025) · American Journal of Translational Research · doi:10.62347/lvro1003 · Cited by 3
The ASO drug olezarsen targets familial chylomicronemia syndrome
Jin, J., Nguyen, L. T. G., Tawfik, S. M., Armanios, B., & Zhong, X. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.05.007 · Cited by 4
Zambon, A., Gentile, L., Galimberti, F., Manzato, E., Giaccari, A., Sesti, G., Belfiore, A., Norata, G. D., Temporelli, P. L., Frulloni, L., et al. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104214 · Cited by 3
Self-citationExome sequencing and analysis of 44,028 British South Asians enriched for high autozygosityPreprint
Kim, H. I., DeBoever, C., Walter, K., Kalantzis, G., Li, C., Mozaffari, S. V., Kundu, K., Jacobs, B. M., Mohammadi‐Shemirani, P., Musolf, A. M., et al. (2025) · medRxiv · doi:10.1101/2025.06.05.25329068 · Cited by 3
Heath, O., Allender, B., Smith, J. D., Savva, E., Spencer, L., Bannister, E. G., Brown, N. J., Evans, M. S., Kiss, S., Rozen, T. H., et al. (2024) · JIMD Reports · doi:10.1002/jmd2.12434 · Cited by 6
“34,35 In separate randomised, placebo-controlled trials involving adults with FCS, Volanesorsen and Olezarsen both significantly reduced triglyceride levels compared to placebo.”
BackgroundTramontano, D., Martino, M. D., Baratta, F., Costanzo, A. D., Cocomello, N., Commodari, D., Bini, S., Minicocci, I., Arca, M., & D’Erasmo, L. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.05.004 · Cited by 3
Self-citationIdiopathic recurrent acute pancreatitis: current and future approaches to management
Singh, P. K., Mahapatra, S. J., & Garg, P. K. (2025) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000001122 · Cited by 2
Hinata, D., Kai, Y., Fukuda, R., Kamada, Y., Kasahara, Y., Sasaki, K., Yoshida, T., Obika, S., Inoué, T., & Okiyoneda, T. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102756 · Cited by 2
“18,19 Previously, we developed amido-bridged nucleic acids (AmNAs), a novel type of BNA.”
Besci, Ö., Güler, M. Ç., Foss‐Freitas, M. C., & Oral, E. A. (2025) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2025.2574318 · Cited by 3
“The patient exhibited only mild reductions in hunger scores and a clinically insignificant decrease in insulin requirements, with no improvement in triglyceride levels or HbA1c [151].”
D’Erasmo, L., Tramontano, D., & Arca, M. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000941 · Cited by 3
Self-citationKessler, A. S., Vera‐Llonch, M., Karwatowska‐Prokopczuk, E., Alexander, V. J., Ann, Q., Herrera, C. M., Paparrodopoulos, S., Xia, S., Stroes, E. S. G., Baum, S. J., et al. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.12.018 · Cited by 2
Self-citationAdvances in antisense oligonucleotide treatment for cancer
Zhu, L., Muhtar, P., Goyama, S., & Yoshimi, A. (2026) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyag017 · Cited by 6
“Moreover, in patients with FCS, olezarsen represents a promising therapeutic option for effectively lowering plasma triglyceride levels [73, 74].”
Bouillet, B., Boulestreau, R., Aboyans, V., Béliard, S., Boccara, F., Cariou, B., Charrière, S., Moulin, P., Vergès, B. L., Valéro, R., et al. (2026) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2026.01.001 · Cited by 2
Adjunctive pharmacological strategies for residual risk reduction after myocardial revascularisation
Oshima, A., Serruys, P. W. J. C., Garg, S., McEvoy, J. W., Wood, D., Doenst, T., Taggart, D. P., Puskas, J. D., Shajahan, A., Sharif, F., et al. (2026) · EuroIntervention · doi:10.4244/eij-d-25-00598 · Cited by 5
Self-citationQi, S., Wang, S., Chen, W., Chen, W., Ni, T., Xu, D., Yang, Z., EnQiang, M. A. O., Erzhen, C. H. E. N., & Chen, Y. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.03.008 · Cited by 2
Rehman, A., Rajdeep, D., Mohnkern, J. D., & Lin, J. (2026) · Digestive Diseases and Sciences · doi:10.1007/s10620-026-09846-1 · Cited by 2
“In both the BALANCE trial [8] and CORE-TIMI [9] trial, acute pancreatitis events were independently adjudicated in a blinded fashion by a central committee and defined according to the Atlanta classification [18] with no potential for surveillance bias across olezarsen and placebo group.”
InfluentialAlterman, J. F., Gross, K. Y., & Khvorova, A. (2026) · Nucleic Acid Therapeutics · doi:10.1177/21593337261435980 · Cited by 3
Mahapatra, S. J., Chowdhury, S. D., Akshintala, V. S., & Garg, P. K. (2026) · Gastroenterology · doi:10.1053/j.gastro.2026.03.027 · Cited by 4
Zadeh, S. S. T., Toth, P. P., & Banach, M. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1789019 · Cited by 2
Expanding the toolbox: Emerging antisense oligonucleotide mechanisms for modulating gene expression
Trew, I., Wilton, S. D., Cale, J. M., & Aung-Htut, M. T. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102953 · Cited by 2
“26,27 Olezarsen is also one of the two approved ASO drugs conjugated to a GalNAc 3 molecule that facilitates efficient uptake into hepatocytes, where it anneals to apolipoprotein C3 ( APOC3 ) mRNA that encodes a protein component of triglyceride-rich lipoproteins (Figure 1A).”
ApoC[III] You Later: A Review of Plozasiran for the Management of Familial Chylomicronemia Syndrome
Yin, E. B., Wanat, M. A., & Wang, E. M. (2026) · Annals of Pharmacotherapy · doi:10.1177/10600280261452675 · Cited by 2
Theodoropoulos, P., Fanaropoulou, N. M., & Manessis, A. (2024) · AACE Clinical Case Reports · doi:10.1016/j.aace.2024.08.006 · Cited by 3
Molecular Therapeutics in Development to Treat Hyperlipoproteinemia
Ahmad, M., & Hegele, R. A. (2025) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-024-00768-0 · Cited by 5
“The first, called BALANCE [68], was a double-blind, randomized, 52-week, phase III trial of 66 adults with FCS, of whom 22 were assigned to the olezarsen 80-mg group, 21 to the olezarsen 50-mg group, and 23 to the placebo group.”
Self-citationReal life evidence of volanesorsen for familial chylomicronemia syndrome in Colombia
Román-Gonzaléz, A., Castellanos, A., Perdomo, D. F. S., Peña, C. A. C., Vargas, J. J., Mendivil, C. O., & Gutiérrez-Restrepo, J. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.04.203 · Cited by 2
Kessler, A. S., Brown, T. M., Bratlee‐Whitaker, E., Fehnel, S. E., Vera‐Llonch, M., Arca, M., Averna, M. R., Baass, A. W., Baum, S. J., Bergeron, J., et al. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.06.014 · Cited by 4
Self-citationOgunniyi, K. E., Aghasili, C. C., Akinmoju, O. D., Olaiya, V. O., Abib, O. M., Odueke, A., Popoola, H. A., Onyenokwe, V., Onaolapo, D., Usman, A.-A. M., et al. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00762-9 · Cited by 3
“In the phase 3 BALANCE trial, it achieved an average 42.5% reduction in fasting triglycerides at 6 months (baseline mean ≈ 2600 mg/dL), with continued effect through 12 months and a notable decrease in acute pancreatitis events [85].”
InfluentialAPOC3 inhibition: The strongest case yet for triglyceride targeting
Shapiro, M. D., & Slipczuk, L. (2025) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2025.09.006 · Cited by 2
Bajaj, A., Oral, E. A., Brown, A. S., Gaudet, D., Alexander, V. J., Karwatowska‐Prokopczuk, E., & Baum, S. J. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101352 · Cited by 2
“A summary of 66 patients with genetically identified FCS from the Balance trial, a phase 3 study of olezarsen, provides a sample of characteristics found in adults with FCS (Table 1) [17].”
InfluentialSelf-citationPechetty, R., Rao, P. S., Deb, T., Shekar, C., & Deepthi, K. (2025) · Indian Journal of Cardiovascular Disease in Women · doi:10.25259/ijcdw_55_2025 · Cited by 2
Novel agents for treating severe hypertriglyceridemia
Wierzbicki, A. S. (2024) · Med · doi:10.1016/j.medj.2024.10.019 · Cited by 1
Raja, A., Shafique, M. A., Raja, S., Mustafa, M. S., Shuja, M. H., Ahmed, M., Alim Ur Rahman, H., & Asghar, M. S. (2025) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001877 · Cited by 1
Kessler, A. S., Aggio, D., Howard, E., Soffer, D. E., Alonso, J., Acaster, S., & Williams, K. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.04.190 · Cited by 2
Pediatric Hypertriglyceridemia: Lipoprotein Metabolism, Etiology, and Management
Moriyama, H., & Ham, J. N. (2025) · Current Pediatrics Reports · doi:10.1007/s40124-025-00349-7 · Cited by 3
ApoC3 Attenuates Platelet Activation Through GPIIb/IIIa Receptor Interaction
Holzer, M., Gruden, E., Ćurčić, S., Cvirn, G., & Marsche, G. (2025) · Cells · doi:10.3390/cells14181411 · Cited by 1
“Newer therapeutics, including Olezarsen, a next-generation ASO, and ARO-apoC3, a small interfering RNA (siRNA), have shown comparable efficacy in reducing apoC3 and triglyceride levels, with improved safety profiles [12,13].”
Yoo, J. H. (2025) · Cardiovascular Prevention and Pharmacotherapy · doi:10.36011/cpp.2025.7.e19 · Cited by 2
“Of note, 71% of participants in the BALANCE study had a history of acute pancreatitis within the prior decade [20].”
Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia
Bergmark, B. A., Marston, N., & Sabatine, M. S. (2025) · New England Journal of Medicine · doi:10.1056/nejmc2515639 · Cited by 1
Heterogeneous nature of severe hypertriglyceridemia in childhood
Ariza, M. J., Rioja, J., Seidel, V., Tolin-Hernani, M., González-Estrada, A., Salazar-Quero, J. C., Muñiz‐Grijalvo, O., Mangas, A., Benavides-Román, M. R., Sitja, M. M., et al. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.12.022 · Cited by 1
Meghashree, N., B, K. C., & Shivaraj, D. R. (2026) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2026.15.1.72 · Cited by 1
CORE Principles in the Management of Severe Hypertriglyceridemia
Morris, P. B. (2026) · New England Journal of Medicine · doi:10.1056/nejme2517580 · Cited by 1
Xiao, Q., Wang, M., Wang, S., Wang, L., & Ding, H. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-025-07647-0 · Cited by 3
“In patients with familial chylomicronemia syndrome (FCS), Olezarsen also markedly reduces the risk of pancreatitis [83].”
Peletier, M. C., Kraaijenhof, J. M., Versloot, M., Koppejan, H., Dzobo, K. E., Alexander, V. J., Tsimikas, S., Stroes, E. S. G., & Kroon, J. (2026) · European Heart Journal Open · doi:10.1093/ehjopen/oeag025 · Cited by 1
“13 Recent clinical trials have reported marked reductions in fasting 15–17 as well as postprandial 17 TG levels in hypertriglyceridemic patients.”
Self-citationHypertriglyceridemia: updates from clinical trials of new agents and real-world registries
Haseef, M., Li, S. C. H., Gaitt, T., Chan, D. C., Pang, J., & Watts, G. F. (2026) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000955 · Cited by 1
The evaluation of plozasiran for the treatment of familial chylomicronemia syndrome
Hang, S., & Hegele, R. A. (2026) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2026.2646166 · Cited by 2
“This conjugation enhances hepatocyte uptake, permitting effective suppression at lower doses with less frequent administration [55].”
InfluentialSelf-citationZhu, Y., Yuan, R., Lu, Z., Zhang, Y., Kang, Z., Feng, X., Zhao, G., Sun, J., Guo, J., Yu, T., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102653 · Cited by 2
ApoC-III inhibition: from regulatory approval to equitable implementation
Gaudet, D., Larouche, M., & Stroes, E. S. G. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01281-z · Cited by 2
Self-citationElbahloul, M. A., Gamal, A., Maihoub, O., Elbaz Hassan, M. M., Attia, M. K., Salah, A. M., Elboraay, T., Awad, A. K., Akoum, A., Elazab, A., et al. (2026) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.70717 · Cited by 1
Emara, A., Mansour, A., Aboeldahab, H. A., Awashra, A., Abbas, O. F., Abdul‐Hafez, H. A., Alsubaiei, A. A., AlSejari, N., Saif, H. S., Shubietah, A. R. M., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70716 · Cited by 2
“Furthermore, in the Balance trial [29], pancreatitis events occurred in the placebo group, whereas only one event each occurred in the 50 and 80 mg Olezarsen groups (rate ratio of 0.12) for pooled olezarsen versus placebo.”
InfluentialKessler, A. S., Batra, K., Amos, Q., Baum, S. J., Soffer, D. E., & Vera‐Llonch, M. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.04.002 · Cited by 4
RNA-Targeted Therapeutics for Lipid Metabolic Disorders: From Bench to Bedside
Ali, I., Qiu, J., Cheang, W. S., Wang, G., & Xu, S. (2026) · Research · doi:10.34133/research.1288 · Cited by 1
“In the phase 3 BALANCE trial, olezarsen reduced TG levels by approximately 60% in patients with FCS and markedly lowered the incidence of acute pancreatitis events (NCT04568434) [ 208 ].”
Remnant cholesterol — The transition from biomarker to risk factor
Rosenson, R. S., Velamuri, D. N., Muntner, P., & Goonewardena, S. N. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120755 · Cited by 4
Kirkpatrick, C. F., & Bittner, V. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.05.224 · Cited by 1
Translating Lipoprotein Genetics Into New Therapies
Hegele, R. A. (2026) · Circulation Research · doi:10.1161/circresaha.126.328828 · Cited by 2
Self-citationHepatic Lipoprotein Production, Cardiometabolic Phenotypes, and Subtypes of Steatotic Liver Disease
Davidson, N. O. (2026) · Circulation Research · doi:10.1161/circresaha.126.327269 · Cited by 2
Hypertriglyceridaemia and its multifaceted mechanisms driving atherosclerotic cardiovascular disease
Li, X., Xu, L., Li, J., Luo, Y., Shen, H., & Zhang, D. (2026) · Lipids in Health and Disease · doi:10.1186/s12944-026-02983-6 · Cited by 3
“Olezarsen, an antisense oligonucleotide designed to target APOC3 mRNA, exhibited robust TG-lowering efficacy in the large Phase III ESSENCE-TIMI 73b trial [92].”
Liang, A., Castillo, Y. C., Bruciaga, L. M. M., Murga, O., Patel, A., Monar, G. V. F., Garcia-Corella, J. F., Uribe, H. J. F., Chintamaneni, S., Guha, S., et al. (2026) · Digestive Diseases and Sciences · doi:10.1007/s10620-026-10052-2 · Cited by 1
“Olezarsen, an antisense oligonucleotide targeting apolipoprotein C-III, has demonstrated substantial TG reductions and fewer pancreatitis episodes in patients with Familial Chylomicronemia Syndrome, although its approval remains limited to selected hereditary hypertriglyceridemia syndromes [58].”
Design of Nanocarriers for Kidney Targeted Delivery of Nucleic Acid Therapeutics
Lee, J. H., Han, J., Park, S., & Mok, H. (2026) · Macromolecular Bioscience · doi:10.1002/mabi.70210 · Cited by 2
Lin, L., Brush, M. N., Nelson, C. B., Alexander, V. J., Xia, S., Gordts, P. L. S. M., & Tsimikas, S. (2026) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2026.101699 · Cited by 2
Self-citationUeda, M. (2024) · Translational Pediatrics · doi:10.21037/tp-24-131 · Cited by 2
“Now, olezarsen has been approved for a “compassionate use” to treat patients with unrelenting pancreatitis due to severe HTG, even in FCS (87-89).”
SMASH: An initiative for equitable access to precision medicine for rare or severe lipid disorders
Larouche, M., Abifadel, M., Catapano, A. L., Cuchel, M., Santos, R. D., Raal, F. J., & Gaudet, D. (2024) · European Atherosclerosis Journal · doi:10.56095/eaj.v3i3.78 · Cited by 1
“Most APOC3i are sophisticated bio-drugs interfering with the APOC3 gene translation, specifically single-stranded antisense oligonucleotides (ASO) or double-stranded small interfering RNA (siRNA) [16, 17].”
Safely lowering triglycerides through ANGPTL4 inhibition
Wulff, A. B. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00988-2 · Cited by 1
Li, Q., Qi, K., Wu, S., Shen, A., & Zhao, L. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117351 · Cited by 2
Letter to the editor – ‘Olezarsen, a liver-directed APOC3 ASO therapy for hypertriglyceridemia’
Leow, M. K. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2432487 · Cited by 1
“In a recent article, the Balance Investigators described the safety and efficacy of olezarsen in a phase 3 clinical trial in patients with familial chylomicronemia syndrome and they noted that side effects included low density lipoprotein (LDL) elevation and thrombocytopenia [2].”
Duell, P. B., & Maki, K. C. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.12.001 · Cited by 1
Plozasiran and Apolipoprotein C-III Inhibition
Schwartz, G. G., & Cobbaert, C. M. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.03.519 · Cited by 1
Weekly Journal Scan: a novel RNA-based approach to the treatment of hypertriglyceridaemia
Galiuto, L., & Volpe, M. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae351 · Cited by 1
Prävention der HTG-bedingten Pankreatitis
Klose, G. (2024) · Gastro-News · doi:10.1007/s15036-024-3712-x
Einsatz von Olezarsen bei Hypertriglyzeridämie und familiärem Chylomikronämiesyndrom
Leitolf, H., & Nitschmann, S. (2024) · Die Innere Medizin · doi:10.1007/s00108-024-01785-1
Moury, J., Nendumba, G., Robert, A., Hauqiert, B., Vornicu, O., Blackman, S., Perriens, E., Bendoumou, M., Sánchez, A., Buttice, E., et al. (2024) · Annals of Translational Medicine · doi:10.21037/atm-24-63
“Meanwhile, more potent drugs like olezarsen, a third-generation antisense oligonucleotide targeting apo-CIII, might offer a better safety profile than volanesorsen, with no drug-induced thrombocytopenia observed in clinical trials (17,18).”
Hooper, A. J., Bell, D. A., & Burnett, J. R. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2437524
Familiäres Chylomikronämie-Syndrom: Olezarsen sicher und wirksam?
Simon, A. (2024) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2360-1869
Quilomicronemia familiar: nuevas perspectivas
Echevarría, A. B., Corbo, M. J. A., Muñiz-Grijalvo, O., & Díaz-Díaz, J. L. (2024) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2024.10.006
Exploring emerging pharmacotherapies for type 2 diabetes patients with hypertriglyceridemia
Tomlinson, B., & Chan, P. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2451752 · Cited by 2
“The Balance trial (NCT04568434) was a phase 3 trial in patients with FCS, in which olezarsen 50 mg or 80 mg or placebo was given SC every 4 weeks for 49 weeks [58].”
Familial chylomicronemia: New perspectives
Echevarría, A. B., Corbo, M. J. A., Muñiz-Grijalvo, O., & Díaz-Díaz, J. L. (2024) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2025.100747
Leveraging drug-target Mendelian randomization for tailored lipoprotein-lipid lowering
Gagnon, É., & Arsenault, B. J. (2025) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000977
The Importance of Hypertriglyceridemia: Risk of Atherosclerosis and Available Treatments
Hegele, R. A. (2025) · Canadian Cardiology Today · doi:10.58931/cct.2025.113
Self-citationDuell, P. B. (2025) · International Journal of Clinical and Translational Medicine · doi:10.53941/ijctm.2025.100008 · Cited by 1
“Adverse event rates were similar for placebo and olezarsen [16].”
InfluentialPankreatitis durch Medikamente – Medikamente zur Behandlung der Pankreatitis
Hubert, M. O., Mayerle, J. V., & Sirtl, S. (2025) · Die Innere Medizin · doi:10.1007/s00108-025-01888-3 · Cited by 1
Alexander, V. J., Prohaska, T. A., Karwatowska‐Prokopczuk, E., Xia, S., & Tsimikas, S. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.05.007
Self-citationEvolving landscape for management of chylomicronemia
Maki, K. C., & Duell, P. B. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.05.012
Арманович, А. А., Kaktursky, L. V., Urazova, O. I., Трофименко, А. И., Sukiasyan, L. M., Коган, Е. А., Демура, Т. А., & Вачиковна, П. Н. (2025) · Bulletin of Siberian Medicine · doi:10.20538/1682-0363-2025-2-124-140 · Cited by 1
Thadchanamoorthy, V., Dayasiri, K. C., Yoganathan, H., Majitha, S. I., Hooper, A. J., & Burnett, J. R. (2025) · Journal of Paediatrics and Child Health · doi:10.1111/jpc.70205
“Several new therapeutic agents are showing promise, including antisense oligonucleotides (ASO) e.g., olezarsen [13] and small interfering RNAs e.g., plozasiran [14].”
Dziewierz, A., Bobrowska, B., Streb, W., Pelliccia, F., Bartuś, S., & Rajtar-Salwa, R. (2025) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2025.2570839 · Cited by 1
“In the pivotal Phase 3 BALANCE trial in patients with FCS, olezarsen demonstrated both a significant reduction in triglyceride levels and a substantial, clinically meaningful reduction in the rate of acute pancreatitis events [103].”
Olezarsen and post-prandial triglyceride levels
Brunham, L. R. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf655
Liu, T., Peng, L., Huo, Y., Lu, T., & Lv, X. (2025) · International Journal of General Medicine · doi:10.2147/ijgm.s542198 · Cited by 1
“21,22 Research has shown that HTG-AP patients with combined fatty liver have International Journal of General Medicine 2025:18 a higher risk of multiple organ failure and death, and a poorer prognosis.”
Metadata
- Authors
- Stroes, E. S. G., Alexander, V. J., Karwatowska-Prokopczuk, E., Hegele, R. A., Arca, M., Ballantyne, C. M., Soran, H., Prohaska, T. A., Xia, S., Ginsberg, H. N., Witztum, J. L., & Tsimikas, S.
- Affiliations
- Western University (CA)
- From the Department of Vascular Medicine, Amsterdam University Medical Center, Amsterdam, (E.S.G.S.); Ionis Pharmaceuticals, Carlsbad (V.J.A., E.K.-P., T.A.P., S.X., S.T.), and the Divisions of Endocrinology and Metabolism (J.L.W.) and Cardiovascular Medicine (S.T.), Department of Medicine, University of California, San Diego, La Jolla — both in California; the Department of Medicine and Robarts Research Institute, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada (R.A.H.); the Department of Translational and Precision Medicine, Center for Rare Disorders of Lipid Metabolism, Sapienza University of Rome, Rome (M.A.); Baylor College of Medicine and the Texas Heart Institute, Houston (C.M.B.); the National Institute for Health Research and Wellcome Trust Clinical Research Facility, Manchester University Hospital NHS Foundation Trust, Manchester, United Kingdom (H.S.); and the Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York (H.N.G.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-05-16
- Volume
- 390
- Issue
- 19
- Pages
- 1781-1792
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4394062061
- Cited by
- 271
- References
- 37
- Citations by year
- 2026: 115 · 2025: 112 · 2024: 44
- FWCI
- 81.10
- Type
- journal article
- Language
- en
- Open access
- green
- pure.amsterdamumc.nl
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- Ionis Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- olezarsen, familial chylomicronemia syndrome, acute pancreatitis, hypertriglyceridemia, apolipoprotein C-III, antisense therapy, triglyceride lowering, hepatic triglyceride synthesis, dose comparison, drug safety and efficacy, adverse events, serious adverse events
- MeSH terms
- Acute Disease, Adult, Aged, Double-Blind Method, Female, Humans, Hyperlipoproteinemia Type I, Male, Middle Aged, Oligonucleotides, Pancreatitis, Triglycerides, Hypertriglyceridemia, Apolipoprotein C-III, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.


